Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
The Business Journals24d
Lilly to pay $2.5B for Boston biotech's lead cancer drug
Eli Lilly and Co., which cemented its place in Boston last year with the opening of a new research and development center, is now buying a cancer program from a Boston biotech. Eli Lilly and Co ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Yahoo Finance2d
Eli Lilly and Company (LLY)
the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5 billion share repurchase program was completed in the fourth ...
Morningstar27d
Thrive Global Works with Eli Lilly and Company to Offer Healthy Behaviors Tools and Resources to Improve Health Outcomes
NEW YORK, Jan. 9, 2025 /PRNewswire/ -- Thrive Global announced today it is working with Eli Lilly and Company to embed behavior change tools and resources onto LillyDirect and into traditional ...
Eli Lilly & Co’s Promising Growth: Accelerated Revenue and Drug Pipeline Advances
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
Yahoo Finance27d
Is Eli Lilly and Company (LLY) the Best Blue Chip Stock to Buy for 2025?
In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... as the Federal Reserve cuts interest rates and the new administration under Donald Trump pushes for fewer ...